Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Adani and executives face expanded U.S. indictment for alleged $250 million bribery scheme, leading to significant financial and political repercussions in India.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Adani and executives face expanded U.S. indictment for alleged $250 million bribery scheme, leading to significant financial and political repercussions in India.